Media ReleasesAuscann Group Holdings

View All Auscann Group Holdings News

AusCann Announces Major Progress Towards Production of Cannabinoid Medicines During FY18


• Undertook comprehensive pharmaceutical development project to create an optimal dosage form cannabinoid medicine

• Signed an agreement with Australia’s leading distributor of pharmaceutical products

• Established a medical outreach program to ensure Australian doctors have access to the necessary information required to prescribe medical cannabis products

• Completed a second harvest in Chile, with a significant increase in yield

• Appointed a Master Grower and entered a cultivation research agreement with Canadian group Jade Cannabis

• Welcomed the Federal Government’s decision to allow the export of manufactured cannabinoid medicines from Australia

• Raised over A$35m post FY18 and is well-funded to continue executing strategic goals

Friday, 31 August 2018 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (AusCann or ‘the Company’) is pleased to provide its preliminary results for the financial year ended 30 June 2018.

For further information please download PDF attached:
Download this document